68Ga-DOTATOC PET/CT提取的全身PET体积参数在高分化神经内分泌肿瘤中的预后价值
本研究回顾性分析84例组织学确诊的高分化神经内分泌肿瘤患者的68Ga-DOTATOC PET/CT,提取全身生长抑素受体表达肿瘤体积(SRETVwb)和全身总病灶生长抑素受体表达(TLSREwb)。中位随访15.5个月,35例(41.7%)疾病进展、14例死亡;SRETVwb>39.1 cm3和TLSREwb>306.8 g与更短的中位TTP显著相关(12个月 vs 未达到;P<0.001)。多因素分析中SRETVwb(P=0.005)是TTP的唯一独立预测因子。
要点
- SRETVwb>39.1 cm3与TLSREwb>306.8 g与更短中位TTP相关(12个月 vs 未达到;P<0.001)。
- 多因素分析中SRETVwb(P=0.005)是TTP的唯一独立预测因子,不受组织学分级和TNM分期影响。
- 作者认为SRETVwb和TLSREwb可预测TTP或总生存,可能在高分化NET管理中具有重要临床效用。
核心结论
- 作者认为,从68Ga-DOTATOC PET/CT提取的SRETVwb和TLSREwb可预测TTP或总生存,可能在高分化神经内分泌肿瘤患者的管理中具有重要临床效用。
研究设计与样本
- 回顾性分析84例组织学确诊的高分化神经内分泌肿瘤患者(51例1级、30例2级、3例3级)的68Ga-DOTATOC PET/CT扫描。
- 由2名操作者基于健康肝脏SUVmax的定制阈值独立分割所有68Ga-DOTATOC高摄取病灶,提取SRETV和TLSRE(=SRETV×SUVmean),并求和得到全身SRETVwb和TLSREwb。
- TTP定义为治愈性手术患者(n=10)的无病生存与不可切除或转移性疾病患者(n=74)的无进展生存的组合。
- 采用Kaplan-Meier分析、log-rank检验和Cox比例风险回归模型计算TTP和总生存。
主要发现
- 中位随访15.5个月后,35例(41.7%)确认疾病进展,14例死亡。
- SRETVwb>39.1 cm3和TLSREwb>306.8 g与更短的中位TTP显著相关(12个月 vs 未达到;P<0.001)。
- 多因素分析中,SRETVwb(P=0.005)是TTP的唯一独立预测因子,不受组织学分级和TNM分期影响。
关键数值与推荐
- SRETVwb阈值>39.1 cm3和TLSREwb阈值>306.8 g与更短中位TTP相关(12个月 vs 未达到;P<0.001)。
- 多因素分析中SRETVwb的P=0.005,为TTP的唯一独立预测因子。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to evaluate the prognostic value of somatostatin receptor tumor burden on 68Ga-DOTATOC PET/CT in patients with well-differentiated (WD) neuroendocrine tumors (NETs). Methods: We retrospectively analyzed the 68Ga-DOTATOC PET/CT scans of 84 patients with histologically confirmed WD NETs (51 grade 1, 30 grade 2, and 3 grade 3). For each PET/CT scan, all 68Ga-DOTATOC-avid lesions were independently segmented by 2 operators using a customized threshold based on the healthy liver SUVmax (LIFEx, version 5.1). Somatostatin receptor-expressing tumor volume (SRETV) and total lesion somatostatin receptor expression (TLSRE = SRETV × SUVmean) were extracted for each lesion, and then whole-body SRETV and TLSRE (SRETVwb and TLSREwb, respectively) were defined as the sum of SRETV and TLSRE, respectively, for all segmented lesions in each patient. Time to progression (TTP) was defined as the combination of disease-free survival in patients undergoing curative surgery (n = 10) and progression-free survival for patients with unresectable or metastatic disease (n = 74). TTP and overall survival were calculated by Kaplan-Meier analysis, log-rank testing, and the Cox proportional-hazards regression model. Results: After a median follow-up of 15.5 mo, disease progression was confirmed in 35 patients (41.7%) and 14 patients died. A higher SRETVwb (>39.1 cm3) and TLSREwb (>306.8 g) correlated significantly with a shorter median TTP (12 mo vs. not reached; P < 0.001). In multivariate analysis, SRETVwb (P = 0.005) was the only independent predictor of TTP regardless of histopathologic grade and TNM staging. Conclusion: According to our results, SRETVwb and TLSREwb extracted from 68Ga-DOTATOC PET/CT could predict TTP or overall survival and might have important clinical utility in the management of patients with WD NETs.
引用
- Thuillier P, Liberini V, Grimaldi S, et al. Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from 68Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors. J Nucl Med. 2021. PMID: 34740949. doi:10.2967/jnumed.121.262652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。